

# HIPK3 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP7540b

## **Specification**

# HIPK3 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

# HIPK3 Antibody (C-term) Blocking Peptide - Additional Information

**Gene ID 10114** 

### **Other Names**

Homeodomain-interacting protein kinase 3, Androgen receptor-interacting nuclear protein kinase, ANPK, Fas-interacting serine/threonine-protein kinase, FIST, Homolog of protein kinase YAK1, HIPK3, DYRK6, FIST3, PKY

Q9H422

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/product/products/AP7540b>AP7540b</a> was selected from the C-term region of human HIPK3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

# **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

# HIPK3 Antibody (C-term) Blocking Peptide - Protein Information

### Name HIPK3

Synonyms DYRK6, FIST3, PKY

### **Function**

Serine/threonine-protein kinase involved in transcription regulation, apoptosis and steroidogenic gene expression. Phosphorylates JUN and RUNX2. Seems to negatively regulate apoptosis by promoting FADD phosphorylation. Enhances androgen receptor-mediated transcription. May act as a transcriptional corepressor for NK homeodomain transcription factors. The phosphorylation of NR5A1 activates SF1 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. In osteoblasts, supports transcription activation: phosphorylates RUNX2 that synergizes with SPEN/MINT to enhance FGFR2- mediated activation of the osteocalcin FGF-responsive element (OCFRE).



Tel: 858.875.1900 Fax: 858.875.1999

# **Cellular Location** Cytoplasm. Nucleus

### **Tissue Location**

Overexpressed in multidrug resistant cells. Highly expressed in heart and skeletal muscle, and at lower levels in placenta, pancreas, brain, spleen, prostate, thymus, testis, small intestine, colon and leukocytes. Not found in liver and lung

### **HIPK3 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

## • Blocking Peptides

HIPK3 Antibody (C-term) Blocking Peptide - Images

## HIPK3 Antibody (C-term) Blocking Peptide - Background

Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the g phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. The STE group (homologs of yeast Sterile 7, 11, 20 kinases) consists of 50 kinases related to the mitogen-activated protein kinase (MAPK) cascade families (Ste7/MAP2K, Ste11/MAP3K, and Ste20/MAP4K). MAP kinase cascades, consisting of a MAPK and one or more upstream regulatory kinases (MAPKKs) have been best characterized in the yeast pheromone response pathway. Pheromones bind to Ste cell surface receptors and activate yeast MAPK pathway.

## HIPK3 Antibody (C-term) Blocking Peptide - References

Blume-Jensen P, et al. Nature 2001. 411: 355. Cantrell D, J. Cell Sci. 2001. 114: 1439. Jhiang S Oncogene 2000. 19: 5590. Manning G, et al. Science 2002. 298: 1912. Moller, D, et al. Am. J. Physiol. 1994. 266: C351-C359.Robertson, S. et al. Trends Genet. 2000. 16: 368.Robinson D, et al. Oncogene 2000. 19: 5548. Van der Ven, P, et al. Hum. Molec. Genet. 1993. 2: 1889. Vanhaesebroeck, B, et al. Biochem. J. 2000. 346: 561. Van Weering D, et al. Recent Results Cancer Res. 1998. 154: 271.